A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy

Figure 1 Structure of the Markov model for chronic hepatitis B.

Figure 2 Total costs at 10 years for drugs and other health costs calculated for a cohort of 100 patients.

Figure 3 Mean cost per patient per year.

Table 1 Input data of the base case scenario

Table 2 Virologic response, HBV resistance, and seroconversion rates for each antiviral drug for both HBeAg-positive and -negative patients

Table 3 Cost data: average cost of different stages of the disease (€, year 2009 values) and annual drug costs

Table 4 Results: costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER) of the base case scenario (10-year horizon)

Figure 4 Results of one-way sensitivity analyses.

Table 5 Results of one-way sensitivity analyses

GaetaGBStornaiuoloGPreconeDFEpidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian studyJ Hepatol20033961036104114642623

GianniniEGTorreFBassoMLigurian Hepatitis B Virus Study Group. A significant proportion of patients with chronic hepatitis B who are candidates for antiviral treatment are untreated: a region-wide survey in ItalyJ Clin Gastroenterol200943101001100719318981

IdrisBIBrosaMRichardusJHEstimating the future health burden of chronic hepatitis B and the impact of therapy in SpainEur J Gastroenterol Hepatol200820432032618334876

MarcellinPHeathcoteEJButiMTenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis BN Engl J Med2008359232442245519052126

HeathcoteJEGaneEJde ManATwo year tenofovir disoproxil fumarate (TDF) treatment and adenofovir dipivoxil (ADV) switch data in HbeAg-positive patients with chronic hepatitis B (Study 103), preliminary analysis [Abstract]Hepatology200848Suppl 4309A

HeathcoteJEGaneEJde ManAThree years of tenofovir disoproxil (TDF) treatment in HbeAg-positive patients (HBeAg+) with chronic hepatitis B (Study 103), preliminary analysis [Abstract]Hepatology200950Suppl 4533A

ChangTTGishRGde ManRA comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis BN Engl J Med2006354101001101016525137

LaiCLYuenMFChronic hepatitis B: new goals, new treatmentN Engl J Med2008359232488249119052131

MarcellinPChangTTLimSGAdefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis BN Engl J Med2003348980881612606735

European Association for the Study of the LiverEASL clinical practice guidelines: management of chronic hepatitis BJ Hepatol200950222724219054588

LaiCLGaneELiawYFTelbivudine versus lamivudine in patients with chronic hepatitis BN Engl J Med2007357252576258818094378

LaiCLGaneEHsuCWTwo-year results from the globe trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LDT) vs lamivudine [Abstract]Hepatology200644Suppl 1222A

MarcellinPButiMKrastevZTwo year tenofovir disoproxil fumarate (TDF) treatment and adenofovir dipivoxil (ADV) switch data in HbeAg-negative patients with chronic hepatitis B (Study 102), preliminary analysis [Abstract]Hepatology200848Suppl 4370A

MarcellinPButiMKrastevZThree years of tenofovir disoproxil (TDF) treatment in HbeAg-positive patients (HBeAg+) with chronic hepatitis B (Study 103), preliminary analysis [Abstract]Hepatology200950Suppl 4532A

Di MarcoVMarzanoALamperticoPItalian Association for the Study of the Liver (AISF) Lamivudine Study Group, Italy. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudineHepatology200440488389115382125

HadziyannisSJTassopoulosNCHeathcoteEJAdefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 yearsGastroenterology200613161743175117087951

SenturkHLurieYGadanoAETV re-treatment of nucleoside-naive HBeAg(–) [Abstract]J Hepatol200746Suppl 1S197

ShouvalDAkarcaUSHatzisGContinued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(–) chronic hepatitis B patients (study ETV-027)J Hepatol200644Suppl 2S21S22

WangYThongsawatSGaneEJEfficacy and safety outcomes after 4 years of telbivudine treatment in patients with chronic hepatitis B (CHB)Hepatology200950Suppl 4533A

Snow-LampartAChappellBJCurtisMHBeAg+ and HBeAg–hepatitis B patients treated with tenofovir df showed no relationship between virologic breakthrough and emergence of genotypic changes in HBV polymeraseHepatology200950Suppl 4523A

LokASLaiCLLeungNLong-term safety of lamivudine treatment in patients with chronic hepatitis BGastroenterology200312561714172214724824

MarcellinPChangTTLimSGLong-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis BHepatology200848375075818752330

TenneyDJRoseREBaldickCJLong-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapyHepatology20094951503151419280622

LiawYFGaneELeungNGLOBE Study Group. 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis BGastroenterology2009136248649519027013

FontanaRJHepatitis B: a “GLOBAL” health challengeGastroenterology2009136238939219109963

ChangTTGishRGde ManRBEHoLD AI463022 Study GroupA comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis BN Engl J Med2006354101001101016525137

BusterEHFlinkHJCakalogluYSustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2bGastroenterology2008135245946718585385

JanssenHLvan ZonneveldMSenturkHHBV 99-01 Study Group; Rotterdam Foundation for Liver Research. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trialLancet2005365945412312915639293

MarcellinPLauGKBoninoFPeginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis BN Engl J Med2004351121206121715371578

MarcellinPBoninoFLauGKPeginterferon alfa-2a in HBeAg-negative Chronic Hepatitis B Study Group. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2aGastroenterology2009136721692179e1e419303414

LauGKCurrent treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversionLiver Int201030451252020102511

LeungNPengCYSollanoJEntecavir (ETV) results in higher HBV DNA reduction versus adefovir (ADV) in antiviralnaive HBeAg+ adults with high HBVDNA: Week 96 results (E.A.R.L.Y. study)J Hepatol200848S373S374

HanSChangT-TChaoYCFour-year entecavir treatment in nucleosidenaïve HBeAg(+) patients: results from studies ETV-022 And -901Hepatology200746(4) Suppl 1654A

HouJYinYKXuDTelbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trialHepatology20084744745418080339

PiratvisuthTLauGChaoYCSustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis BHepatol Int20082110211019669285

Health MinistryNational Tariff Nomenclature. Nomenclatore delle Prestazioni di assistenza specialistica ambulatoriale Ministero della Salute2010

Conferenza delle Regioni e delle Province autonome 1O/014/CR10a/C7. DRG 206, Tariffa Unica Convenzionale (TUC) per le prestazioni di assistenza ospedaliera, regole e tariffe valide per l’anno 2009secondo CMS-DRG Versione 24. DRG 206; DRG 202; DRG 199; DRG 480; Roma2010

TumiattiCBezzonCGuastiFFranchinM Il costo del trapianto d’organo: risultati di uno studio condotto presso l’Azienda Ospedaliera di Padova. Azienda Ospedaliera di Padova. 1999:39. valori attualizzati al 2009

Gazzetta Ufficiale n 216 of 14/09/1996: DM 22/07/1996; 89.7: visita specialistica, prima visita. Prestazioni di assistenza specialistica ambulatoriale erogabili nell’ambito del Servizio sanitario nazionale e relative tariffe

Gazzetta Ufficiale n 216 of 14/09/1996: DM 22/07/1996;90.16.3: creatinina, 90.24.3 fosfato organico. Prestazioni di assistenza specialistica ambulatoriale erogabili nell’ambito del Servizio sanitario nazionale e relative tariffe